Gene editing delivery vectors serve as the physical and biochemical packaging systems that carry editing machinery—nuclease proteins, encoding mRNA, guide RNAs, donor DNA templates, or ribonucleoprotein (RNP) complexes—across cellular and intracellular barriers. Among retrieved results, two primary delivery paradigms are represented: viral vectors (AAV, lentiviral, adenoviral, baculoviral, and hybrid systems) and non-viral vectors (lipid-based systems, peptide-based carriers, plasmid and nanoplasmid DNA, episomal DNA nanovectors, and virus-like particles).

The core technical challenge, consistently identified across this dataset, is the tension between payload capacity and safety: viral vectors offer high transduction efficiency but risk insertional mutagenesis, immunogenicity, and cargo size constraints, while non-viral vectors provide improved safety profiles but have historically suffered from low transfection efficiency. A third, emerging category—engineered hybrid and cell-free systems (eVLPs, baculovirus-derived SVNs, closed-ended DNA vectors)—is converging these advantages.

Key nuclease payloads discussed across sources include Cas9 and base editors (CRISPR/Cas9), ZFNs, TALENs, and meganucleases, each imposing distinct size and delivery constraints on the vector platform. Authoritative overviews of gene therapy vector safety are maintained by the FDA and the EMA, while foundational genomic editing frameworks are tracked by the WHO Human Genome Editing Registry. For comprehensive patent landscape analysis across these platforms, PatSnap Analytics provides structured IP intelligence across all vector categories.

1. Closed-Ended DNA (ceDNA) and Nanoplasmid Vectors as AAV Alternatives. Generation Bio's ceDNA platform (2020, SG/IL) and Aldevron's Nanoplasmid work (2023) directly target the limitations of AAV—pre-existing immunity, cargo constraints, manufacturing cost. ceDNA vectors are linear, non-integrating, and can encode full gene-editing cassettes including gRNAs and HDR templates within a single particle. This is among the most commercially active emerging directions in the dataset.

2. Engineered Virus-Like Particles (eVLPs) for RNP Delivery. The University of Minnesota eVLP system (2022) achieving 63% liver editing with base editors as protein cargo signals convergence on protein/RNP delivery as a means of avoiding nucleic acid persistence and reducing immunogenicity. Fourth-generation eVLP engineering addresses packaging, release, and localization bottlenecks that limited earlier generations. Research on VLP safety is tracked by the NIH.

3. Immuno-Evasive and Targeted Enveloped Vectors. Chameleon Biosciences' pending patents (IL/SG, 2020) incorporating CTLA4, PD-L1, and cell-targeting antibodies into viral envelope membranes represent a nascent but patent-active direction for overcoming the primary immune barrier to repeated in vivo dosing.

4. Machine Learning-Guided AAV Capsid Engineering. University of Heidelberg (2022) documents ML-driven random diversification and rational design of AAV capsids for tissue-specific tropism. This approach enables rapid generation of next-generation capsid variants that can evade pre-existing immunity and achieve CNS, retinal, or hepatic targeting beyond what natural AAV serotypes allow. For chemicals and materials IP intelligence relevant to capsid formulation, see PatSnap Chemicals & Materials.

5. Non-Viral Episomal Platforms for Ex Vivo T Cell Manufacturing. The Heidelberg University nonviral nanovector platform (2021) for CAR-T manufacturing and the TOP vector for primary T cells (Fred Hutchinson, 2021) both signal movement toward reducing reliance on integrating retroviral/lentiviral vectors in cell therapy manufacturing, addressing regulatory and safety concerns around insertional mutagenesis.

6. Plant Genome Editing Delivery. Emerging literature (UC Davis, 2022; Peking University, 2022) on viral RNA vector-mediated heritable base editing and nanomaterial delivery to crops indicates agricultural gene editing delivery is becoming a distinct sub-field, particularly relevant given genotype-independence requirements for crop species. Patent databases tracked by the EPO are increasingly indexing agricultural gene editing IP.